relugolix

{
  "id": "MLC-T-ONC-007326",
  "term": "relugolix",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with advanced prostate cancer. Relugolix binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, which blocks the pituitary gland from making the hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This causes the testicles to stop making testosterone. Relugolix may stop the growth of cancer cells that need testosterone to grow. It is a type of GnRH antagonist. Also called Orgovyx.",
    "An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation."
  ],
  "synonyms": [
    "Orgovyx",
    "N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/relugolix/"
}